XML 18 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Document and Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2024
Mar. 27, 2025
Jun. 30, 2024
Document Information [Line Items]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2024    
Document Transition Report false    
Entity File Number 00-50626    
Entity Registrant Name Cyclacel Pharmaceuticals, Inc.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 91-1707622    
Entity Address, Address Line One Level 10, Tower 11    
Entity Address, Address Line Two Avenue 5, No. 8    
Entity Address, City or Town Kuala Lumpur    
Entity Address, Country MY    
Entity Address, Postal Zip Code 592000    
City Area Code 908    
Local Phone Number 517-7330    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Public Float     $ 2,523,882
Entity Common Stock, Shares Outstanding   207,336,389  
Current Fiscal Year End Date --12-31    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Entity Central Index Key 0001130166    
Amendment Flag false    
Auditor Name Bush & Associates CPA LLC    
Auditor Firm ID 6797    
Auditor Location Henderson, Nevada    
DOCUMENTS INCORPORATED BY REFERENCE

​

The following document (or parts thereof) are incorporated by reference into the following parts of this Form 10-K: Certain information required in Part III of this Annual Report on Form 10-K is incorporated from the registrant’s definitive proxy statement for the 2025 annual meeting of stockholders to be filed pursuant to Regulation 14A with the Securities and Exchange Commission within 120 days of the registrant’s fiscal year ended December 31, 2024. Except with respect to information specifically incorporated by reference in this Form 10-K, the Definitive Proxy Statement is not deemed to be filed as part of this Form 10-K.

    
Common Stock      
Document Information [Line Items]      
Title of 12(b) Security Common Stock, par value $0.001 per share    
Trading Symbol CYCC    
Security Exchange Name NASDAQ    
Preferred Stock      
Document Information [Line Items]      
Title of 12(b) Security Preferred Stock, $0.001 par value    
Trading Symbol CYCCP    
Security Exchange Name NASDAQ